Lv61
1810 积分 2022-07-07 加入
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
11天前
已完结
Medication adherence part two: Predictors of nonadherence and adherence
15天前
已关闭
Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer
15天前
已完结
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
18天前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
21天前
已完结
New and emerging targeted treatments in advanced non-small-cell lung cancer
27天前
已完结
Cancer incidence and mortality in China, 2022
27天前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
28天前
已完结
The Drug-Dosing Conundrum in Oncology — When Less Is More
28天前
已完结
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
28天前
已完结
皖公网安备34019202002308
